SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?


To: erickerickson who wrote (38484)1/6/2017 8:42:03 PM
From: erickerickson  Read Replies (1) | Respond to of 63293
 
Two more categories popped into my mind while getting ready to go out to dinner.

7: Amateurish missteps:
- fiASCO comes to mind most recently.

8: Deals that weren't
- most recently for 132 but then "whoops, let's do a financing instead"

In the interests of "fair and balanced reporting", I'd also be happy to create a second section to my summary about "why the venBio proxy should be defeated". I confess I'll need a lot more help with that one. I suppose it all boils down to "venBio may have nefarious motives", 'cause I'm not coming up with other reasons.



To: erickerickson who wrote (38484)1/7/2017 12:18:28 AM
From: allatwwk3 Recommendations

Recommended By
idahoranch1
ladyPI
summer_sky

  Respond to of 63293
 
Erick -- my main issue with IMMU mgmt is simple enough. They never figured out what they were genuinely good at and genuinely bad at.

This biz should have been partnering up every molecule they could at the earliest possible stage. This would have let them do what they do best, which is run a development lab and develop new drugs.

Instead, they spent money, time and energy taking trials far further than they should have gone on their own dime. They failed to acquire expertise in partnering, which is the one critical complement needed for a lab oriented business. They wanted to control all the marbles, and its been a terrible approach to running the business, especially one with very limited cash. Couple this with ill-timed financings and here we are.